LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript Summary
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript Summary
Operating income saw a robust increase of 43% to $13.1 million with operating margins improving to 24%, reflecting restrained operating expense growth and operational efficiencies.The following is a summary of the LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript:
以下是勒梅特微管醫療公司（LMAT）2024年第三季度業績會交易摘要：
Financial Performance:
金融業績：
LeMaitre Vascular reported a 16% sales growth for Q3 2024, driven primarily by graphs, patches, and carotid shunts with a notable increase in APAC, especially Thailand and Korea.
Gross margin improved significantly to 67.8%, a rise of 280 basis points year-over-year, attributed to higher Average Selling Prices (ASPs) and direct labor efficiencies.
Operating income saw a robust increase of 43% to $13.1 million with operating margins improving to 24%, reflecting restrained operating expense growth and operational efficiencies.
勒梅特微管醫療報告稱，2024年第三季度銷售額增長了16%，主要受到圖表、貼片和頸動脈分流器的推動，尤其是亞太地區，特別是泰國和韓國有顯着增長。
毛利率顯著提高至67.8%，同比增加280個點子，歸因於更高的平均銷售價格（ASPs）和直接勞動效率的提高。
營業收入大幅增長43%至1310萬美元，營業利潤率提高至24%，反映出控制的營業費用增長和運營效率的提高。
Business Progress:
業務進展：
LeMaitre Vascular has made substantial progress with its international expansion, specifically by establishing direct sales operations in Thailand and Korea and expanding brick-and-mortar offices in key locations like Paris and Zurich.
The company continues to strengthen its regulatory position with 15 out of 22 MDR CE marks received, with expectations to secure the remaining approvals in 2025.
Continued investment in hiring, with a sales force growth to 149 representatives and expansion plans to achieve 155 to 160 representatives by year-end. This includes focusing on increased manpower for management and sales operations through new hires and the creation of new roles.
勒梅特微管醫療在國際擴張方面取得了實質性進展，特別是通過在泰國和韓國建立直銷業務，並在巴黎和蘇黎世等關鍵地點擴大實體辦公室。
該公司繼續加強其監管地位，已獲得22項MDR CE標誌中的15項，預計將在2025年獲得其餘的批准。
持續投資於招聘，銷售團隊增長至149名代表，並計劃在年底實現155至160名代表。這包括專注於通過新員工和新角色的創設，爲管理和銷售業務增加勞動力資源。
Opportunities:
機會：
LeMaitre's strategic focus on expanding directly into new markets and increasing control over sales and distribution channels, notably in European markets such as Portugal and Czechia, aligns with market expansion opportunities.
The introduction of pricing floors and structured sales strategies in multiple geographies offer an operational efficiency opportunity by standardizing pricing mechanisms to ensure consistent revenue growth.
勒梅特微管醫療戰略性地專注於直接拓展新市場，並加強對銷售和分銷渠道的控制，尤其是在歐洲市場，如葡萄牙和捷克。與市場拓展機會保持一致。
在多個地理區域引入底價和結構化銷售策略，爲操作效率機會提供標準化定價機制，以確保一致的營業收入增長。
Risks:
風險：
The gradual growth expectation from AI services as they scale presents a potential delay in achieving peak market penetration rates, impacting projected revenue trajectories in emerging technologies.
隨着人工智能服務規模的逐步增長，對於潛在延遲達到最高市場滲透率的期望增長，影響了新興技術預期的營業收入發展軌跡。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
